



Software for  
Business Intelligence

**BizInt Smart Charts**

Patents & IP Sequences | Clinical Trials | Drug Pipelines



# Creating IP Reports Integrating Sequence, Hit Structure, and Family data with BizInt Smart Charts

PIUG 2018 Biotechnology Conference, Boston MA

*John Willmore*

20 February 2017

[www.bizint.com](http://www.bizint.com)

# Agenda

- Building IP Sequence reports
- GenomeQuest data enhancements
- Hit Structure reports
- Other data types

# Agenda

- Building IP Sequence reports
- GenomeQuest data enhancements
- Hit Structure reports
- Other data types



# BizInt Smart Charts

VERSION

4

*for Patents*

## IP Sequence Databases


*Provide data on sequences filed in patents*

- GQ Life Sciences GenomeQuest (Geneseq, GQ-PAT)
- STN (USGENE, DGENE, PCTGEN)






# Export your search results



The screenshot displays the BizInt Smart Charts website interface. At the top, the logo features a stylized 'L' icon and the text 'Software for Business Intelligence BizInt Smart Charts'. To the right, contact information includes an email 'help: support@bizint.com' and a phone number '1.714.289.1000 [8am - 5pm Pacific]'. A search bar is positioned below the contact details. The main navigation bar contains links for 'Home', 'Products', 'Support', 'News & Events', 'About Us', and 'Contact Us'. The 'Support' dropdown menu is open, showing options: 'About Support', 'Creating Reports from Databases and Hosts' (highlighted by a mouse cursor), 'Tips for Using BizInt Smart Charts', 'Installation and IT Issues', 'Subscribe to Release Announcements', and 'Standard License Agreement'. On the right side, a sidebar lists additional resources: 'Tips For Using BizInt Smart Charts', 'Cookbook of Reports & Visualizations', 'Software Download', 'Download a Free Trial', and 'Upcoming Events' (IC-SDV 2018, 23-24 April 2018, Nice, France). The main content area features a large image of a brown dog lying on grass, with the text 'Get started with tools and clinical data' and a 'Try it with your own data! DOWNLOAD' button. At the bottom, there are five small square icons and the text 'BizInt Smart Charts Drug Development Suite'.

# Export from GenomeQuest



Software for  
Business Intelligence

**BizInt Smart Charts**

help: support@bizint.com 1.714.289.1000 [8am - 5pm Pacific]

search

Home Products ▾ Support ▾ News & Events ▾ About Us Contact Us

## Support

- About Support
- Creating Reports from Hosts
  - Ovid
  - STN Classic
  - New STN
  - ProQuest Dialog
  - Questel/Orbit
  - SciFinder
  - InfoDesk PipelinePlus
- Creating Reports from Databases
  - Adis Insight
  - ClinicalTrials.gov
  - Cortellis
  - Derwent Innovation
  - EudraCT
  - GenomeQuest
  - Integrity
  - PatBase

### Support: Creating Reports from Databases/Hosts

## Creating from GenomeQuest

BizInt Smart Charts for Patents can build charts from search results from GenomeQuest.

Additional details are provided in this [pdf](#) document.

### Step by Step

1. Create your results set on GenomeQuest.
2. Click on the "Applications" drop-down menu and select "BizInt Smart Charts", as shown below.

Result ▾ Export ▾ Applications ▾ ?

Match ☒ all of the foll

Application pub. date

Abstract

Patent number

Assembly ▶

EMBOSS ▶ g

Geneious

Patent Statistics

To UCSC Genome Browser

**Bizint Smart Charts**

Clustalw

Sequence Search

© 2018 BizInt S

6

# Features of IP Sequences in BizInt reports

- Each row corresponds to a sequence in the context of a query.
- Columns contain bibliographic data, sequence details, and query results.
- You may see the same sequence more than once in a report.
- Family equivalents are not removed.

# Sample sequence data report

## GQPAT Proteins: Antibodies\_GenomeQuest

	Title	Patent Assignee	Seq. ID Number	Organism Species	Alignment	Percentage
1	Nucleic acid sequences relating to <i>Bacteroides fragilis</i> for diagnostics and therapeutics	OSCIENT PHARMACEUTICALS CORPORATION WALTHAM, MA	US7090973-6862	<i>Bacteroides fragilis</i>	Q: 1 KV--SNR-LY 7           S: 340 KVDMSNRILY 349	70.00
2	Expression of microbial proteins in plants for production of plants with improved properties	MONSANTO TECHNOLOGY, LLC ST. LOUIS, MO	US7314974-14121	<i>Pseudomonas fluorescens</i>	Q: 1 K-VS--NRLY 7           S: 597 KLVSDLNRLY 606	70.00
3	Production and use of novel peptide-based agents for use with bi-specific antibodies	IMMUNOMEDICS INC. MORRIS PLAINS, NJ	US6962702-0008	Artificial Sequence	Q: 1 RSSQSIVHSNGNTYLQ 16        + S: 24 RSSQSIVHSNGNTYLE 39	93.75
4	Chimeric, human and humanized anti-CSAP monoclonal antibodies	IMMUNIMEDICS, INC. MORRIS PLAINS, NJ	US7387772-0032	Murine sp.	Q: 1 RSSQSIVHSNGNTYLQ 16        + S: 24 RSSQSIVHSNGNTYLE 39	93.75
5	Chimeric, human and humanized anti-CSAp monoclonal antibodies	IMMUNOMEDICS, INC. MORRIS PLAINS, NJ	US7414121-0032	Murine sp.	Q: 1 RSSQSIVHSNGNTYLQ 16        + S: 24 RSSQSIVHSNGNTYLE 39	93.75
6	Production and use of novel peptide-based agents for use with bi-specific antibodies	IMMUNOMEDICS, INC. MORRIS PLAINS, NJ	US7429381-0008	Artificial Sequence	Q: 1 RSSQSIVHSNGNTYLQ 16        + S: 24 RSSQSIVHSNGNTYLE 39	93.75
7	Production and use of novel peptide-based agents for use with bi-specific antibodies	IMMUNOMEDICS INC. MORRIS PLAINS, NJ	US6962702-0012	Artificial Sequence	Q: 1 RSSQSIVHSNGNTYLQ 16        + S: 24 RSSQSIVHSNGNTYLE 39	93.75
8	Production and use of novel peptide-based agents for use with bi-specific antibodies	IMMUNOMEDICS, INC. MORRIS PLAINS, NJ	US7429381-0012	Artificial Sequence	Q: 1 RSSQSIVHSNGNTYLQ 16        + S: 24 RSSQSIVHSNGNTYLE 39	93.75
9	Covalently reactive transition state analogs and methods of use thereof	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM AUSTIN, TX	US6855804-0042	<i>Mus musculus domesticus</i>	Q: 1 RSSQSIVHSNGNTYLQ 16        + S: 24 RSSQSIVHSNGNTYLE 39	93.75
	Covalently reactive transition state analogs and methods of use thereof	ADLER; BENJAMIN	US7524663-0042	<i>Mus musculus domesticus</i>	Q: 1 RSSQSIVHSNGNTYLQ 16        + S: 24 RSSQSIVHSNGNTYLE 39	93.75



# Sample sequence data report - features

GQPAT Proteins: Antibodies_GenomeQuest						
	Title	Patent Assignee	Organism Species	Alignment		Percentage
1	Nucleic acid sequences relating to Bacteroides fragilis for diagnostics and therapeutics	OSCIENT PHARMACEUTICALS CORPORATION WALTHAM, MA	Bacteroides fragilis	Q:	1 KV--SNR-LY 7	70.00
2				S:	340 KVDMSNRILY 349	
3	Expression of microbial proteins in plants for production of plants with improved properties	MONSANTO TECHNOLOGY, LLC ST. LOUIS, MO	Pseudomonas fluorescens	Q:	1 K-VS--NRLY 7	70.00
4	Production and use of novel peptide-based agents for use with bi-specific antibodies	IMMUNOMEDICS INC. MORRIS PLAINS, NJ	Artificial Sequence	S:	597 KLVSDLNRLY 606	93.75
5				Q:	1 RSSQSIVHSNGNTYLQ 16	
6	Chimeric, human and humanized anti-CSAp monoclonal antibodies	IMMUNOMEDICS, INC. MORRIS PLAINS, NJ	Murine sp.	S:	24 RSSQSIVHSNGNTYLE 39	93.75
7				Q:	1 RSSQSIVHSNGNTYLQ 16	
8	Production and use of novel peptide-based agents for use with bi-specific antibodies	IMMUNOMEDICS, INC. MORRIS PLAINS, NJ	Artificial Sequence	S:	24 RSSQSIVHSNGNTYLE 39	93.75
9				Q:	1 RSSQSIVHSNGNTYLQ 16	
	Production and use of novel peptide-based agents for use with bi-specific antibodies	IMMUNOMEDICS INC. MORRIS PLAINS, NJ	Mus musculus domesticus	S:	24 RSSQSIVHSNGNTYLE 39	93.75
				Q:	1 RSSQSIVHSNGNTYLQ 16	
			Mus musculus domesticus	Q:	1 RSSQSIVHSNGNTYLQ 16	93.75

Bibliographic Data

# Sample sequence data report - features

GQPAT Proteins: Antibodies_GenomeQuest						
	Title	Patent Assignee	Seq. ID Number	Organism Species	Alignment	Percentage
1	Nucleic acid sequences relating to <i>Bacteroides fragilis</i> for diagnostics and therapeutics	OSCIENT PHARMACEUTICAL CORPORATION WALTHAM, MA	US7090973-6862	<i>Bacteroides fragilis</i>	1 KV--SNR-LY 7           340 KVDMSNRILY 349	70.00
2	Expression of microbial proteins in plants for production of plants with improved properties	MONSANTO TECHNOLOGY, LLC ST. LOUIS, MO	US7314974-14121	<i>Pseudomonas fluorescens</i>	1 K-VS--NRLY 7           597 KLVSDLNRLY 606	70.00
3	Production and use of novel peptide-based agents for use with bi-specific antibodies	IMMUNOMEDICS INC MORRIS PLAINS, N.J.	US6962702-0008	Artificial Sequence	1 RSSQSIVHSNGNTYLQ 16      + 24 RSSQSIVHSNGNTYLE 39	93.75
4	Chimeric, human and humanized anti-CSAP monoclonal antibodies	IMMUNOMEDICS, INC MORRIS PLAINS, N.J.			1 RSSQSIVHSNGNTYLQ 16      + 24 RSSQSIVHSNGNTYLE 39	93.75
5	Chimeric, human and humanized anti-CSAp monoclonal antibodies	IMMUNOMEDICS, INC MORRIS PLAINS, N.J.			1 RSSQSIVHSNGNTYLQ 16      + 24 RSSQSIVHSNGNTYLE 39	93.75
6	Production and use of novel peptide-based agents for use with bi-specific antibodies	IMMUNOMEDICS, INC MORRIS PLAINS, N.J.			1 RSSQSIVHSNGNTYLQ 16      + 24 RSSQSIVHSNGNTYLE 39	93.75
7	Production and use of novel peptide-based agents for use with bi-specific antibodies	IMMUNOMEDICS, INC MORRIS PLAINS, N.J.	US7414121-0032	Murine sp.	1 RSSQSIVHSNGNTYLQ 16      + 24 RSSQSIVHSNGNTYLE 39	93.75
8	Production and use of novel peptide-based agents for use with bi-specific antibodies	IMMUNOMEDICS, INC MORRIS PLAINS, N.J.	US7429381-0008	Artificial Sequence	1 RSSQSIVHSNGNTYLQ 16      + 24 RSSQSIVHSNGNTYLE 39	93.75
9	Covalently reactive transition state analogs and methods of use thereof	BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM AUSTIN, TX	US6962702-0012	Artificial Sequence	1 RSSQSIVHSNGNTYLQ 16      + 24 RSSQSIVHSNGNTYLE 39	93.75
	Covalently reactive transition state analogs and methods of use thereof	ADLER; BENJAMIN			1 RSSQSIVHSNGNTYLQ 16      + 24 RSSQSIVHSNGNTYLE 39	93.75

Sequence Data

# Sample sequence data report - features

GQPAT Proteins: Antibodies_GenomeQuest						
	Title	Patent Assignee	Seq. ID Num	Alignment		
1	Nucleic acid sequences relating to <i>Bacteroides fragilis</i> for diagnostics and therapeutics	OSCIENT PHARMACEUTICALS CORPORATION WALTHAM, MA	US7090973-6	Q:	1 KV--SNR-LY 7	70.00
				S:	340 KVDMSNRILY 349	
2	Expression of microbial proteins in plants for production of plants with improved properties	MONSANTO TECHNOLOGY, LLC ST. LOUIS, MO	US7314974-1	Q:	1 K-VS--NRLY 7	70.00
				S:	597 KLVS DLNRLY 606	
3	Production and use of novel peptide-based agents for use with bi-specific antibodies	IMMUNOMEDICS INC. MORRIS PLAINS, NJ	US6962702-0	Q:	1 RSSQSIVHSNGNTYLQ 16	93.75
				S:	24 RSSQSIVHSNGNTYLE 39	
4	Chimeric, human and humanized anti-CSAP monoclonal antibodies	IMMUNIMEDICS, INC. MORRIS PLAINS, NJ	US7387772-0	Q:	1 RSSQSIVHSNGNTYLQ 16	93.75
				S:	24 RSSQSIVHSNGNTYLE 39	
5	Chimeric, human and humanized anti-CSAp monoclonal antibodies	IMMUNOMEDICS, INC. MORRIS PLAINS, NJ	US7414121-0	Q:	1 RSSQSIVHSNGNTYLQ 16	93.75
				S:	24 RSSQSIVHSNGNTYLE 39	
6	Production and use of novel peptide-based agents for use with bi-specific antibodies	IMMUNOMEDICS, INC. MORRIS PLAINS, NJ	US7429381-0	Q:	1 RSSQSIVHSNGNTYLQ 16	93.75
				S:	24 RSSQSIVHSNGNTYLE 39	
7	Production and use of novel peptide-based agents for use with bi-specific antibodies	IMMUNOMEDICS INC. MORRIS PLAINS, NJ	US6962702-0	Q:	1 RSSQSIVHSNGNTYLQ 16	93.75
				S:	24 RSSQSIVHSNGNTYLE 39	
8	Production and use of novel peptide-based agents for use with bi-specific antibodies	IMMUNOMEDICS, INC. MORRIS PLAINS, NJ	US7429381-0	Q:	1 RSSQSIVHSNGNTYLQ 16	93.75
				S:	24 RSSQSIVHSNGNTYLE 39	
9	Covalently reactive transition state analogs and methods of use thereof	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM AUSTIN, TX	US6855804-0	Q:	1 RSSQSIVHSNGNTYLQ 16	93.75
				S:	24 RSSQSIVHSNGNTYLE 39	
	Covalently reactive transition state analogs and methods of use thereof	ADLER; BENJAMIN	US7524663-0	S:	24 RSSQSIVHSNGNTYLE 39	

Query Results

# About the Alignment Column

- The Alignment column appears in the same default font as all columns
- You might be tempted to change the font to Courier New – DON'T!
- **Text menu | Fixed Width (e.g. Alignment)** is the correct technique
- Preserves runs of whitespace when exporting to HTML, Word, or Excel



# Features of IP Sequences in BizInt reports

	Title	Alignment	Alignment Style
1	HEPATITIS C VIRUS GENE	Q: 1 MSTNPKPQRKTKRNTNRRPQDVKFPGGGQIVGGVYLLPRRGPRLGVRATRKTSESRQPRG 60       S: 1 MSTNPKPQRKTKRNTNRRPQDVKFPGGGQIVGGVYLLPRRGPRLGVRATRKTSESRQPRG 60  Q: 61 RRQPIPKDRRSTGKSWGKPGYPWPLYGNEGCGWAGWLLSPRGSRPTWGPTDPRHRSRNLG 120        + ++  +              +            [CONT.]	Default
2	HCV GENE	Q: 1 MSTNPKPQRKTKRNTNRRPQDVKFPGGGQIVGGVYLLPRRGPRLGVRATRKTSESRQPRG 60       S: 1 MSTNPKPQRKTKRNTNRRPQDVKFPGGGQIVGGVYLLPRRGPRLGVRATRKTSESRQPRE 60  Q: 61 RRQPIPKDRRSTGKSWGKPGYPWPLYGNEGCGWAGWLLSPRGSRPTWGPTDPRHRSRNLG 120          ++  +                          [CONT.]	Changed Font
3	HCV GENE	Q: 1 MSTNPKPQRKTKRNTNRRPQDVKFPGGGQIVGGVYLLPRRGPRLGVRATRKTSESRQPRG 60       S: 1 MSTNPKPQRKTKRNTNRRPQDVKFPGGGQIVGGVYLLPRRGPRLGVRATRKTSESRQPRE 60  Q: 61 RRQPIPKDRRSTGKSWGKPGYPWPLYGNEGCGWAGWLLSPRGSRPTWGPTDPRHRSRNLG 120          ++  +                          [CONT.]	Text   Fixed Width

# Features of IP Sequences in BizInt reports

## GQPAT Gold+ Proteins: hepc\_claimed\_gqprt

	Title	Alignment	Alignment Style
1 Link	HEPATITIS C VIRUS GENE	Q: 1 MSTNPKPQRKTKRNTNRRPQDVKFPGGGQIVGGVYLLPRRGPRLGVRATRKTSESRQPRG 60       S: 1 MSTNPKPQRKTKRNTNRRPQDVKFPGGGQIVGGVYLLPRRGPRLGVRATRKTSESRQPRG 60  Q: 61 RRQPIPKDRRSTGKSWGKPGYPWPLYGNEGCGWAGWLLSPRGSRPTWGPTDPRHRSRNLG 120         +  ++  +                      +                [CONT.]	Default
2 Link	HCV GENE	Q: 1 MSTNPKPQRKTKRNTNRRPQDVKFPGGGQIVGGVYLLPRRGPRLGVRATRKTSESRQPRG 60       S: 1 MSTNPKPQRKTKRNTNRRPQDVKFPGGGQIVGGVYLLPRRGPRLGVRATRKTSESRQPRE 60  Q: 61 RRQPIPKDRRSTGKSWGKPGYPWPLYGNEGCGWAGWLLSPRGSRPTWGPTDPRHRSRNLG 120          ++  +                            [CONT.]	Changed Font
3 Link	HCV GENE	Q: 1 MSTNPKPQRKTKRNTNRRPQDVKFPGGGQIVGGVYLLPRRGPRLGVRATRKTSESRQPRG 60       S: 1 MSTNPKPQRKTKRNTNRRPQDVKFPGGGQIVGGVYLLPRRGPRLGVRATRKTSESRQPRE 60  Q: 61 RRQPIPKDRRSTGKSWGKPGYPWPLYGNEGCGWAGWLLSPRGSRPTWGPTDPRHRSRNLG 120          ++  +                            [CONT.]	Text   Fixed Width

# Customize your reports

- Select and **rearrange columns**
- **Add** your own columns.
- Create and apply **chart templates**.
- **Hide rows** that aren't of interest.
- **Sort** by multiple values, **move rows**.
- **Edit text and highlight cells**.
- **Options for truncation** and full text links.
- Tools|Statistics: simple **statistics** can help analyze search results.

# Combining Charts

- You can combine two or more charts into a single report
- BizInt Smart Charts usually removes duplicate rows when combining
- Combining different queries? Use the “Combine without removing duplicates” option in the Combine wizard
- See 2013 PIUG Biotech presentation for more details (@ [bizint.com/slides](http://bizint.com/slides))



# Combining multiple queries

Create Combined Chart Wizard

Step 3 - Select options for new combined chart:

Enter new chart title:

Sequence results - three queries

Select the operation you would like to perform:

☒ **Combine charts from different databases.**  
Build a report from different sources, aligning common fields.

☐ **Add additional results from same search.**  
Create one report from results saved in several files

Finish

< Back

Cancel

Help

Advanced...

**★ Combine without removing duplicates.**  
Useful for gene sequence charts from multiple queries.

# Preserving Multiple Queries

- First combine non-sequence charts with standard options (remove duplicates)
- Then combine the resulting non-sequence chart with the sequence results (without removing duplicates)
- Only use “without removing duplicates” option when you want to see variations on a row “side by side”

# Tools for integrating patent data

- **Combine charts** using **File|Combine** command
- **Identify related records** using the **“Identify Common Patent Family”** tool.

**BizInt Smart Charts**

*for Patents*

# Tools for integrating patent data

- **Combine charts** using **File|Combine** command
- **Identify related records** using the **“Identify Common Patent Family”** tool.
- Use **BizInt Smart Charts Reference Rows** to summarize related records in a single row.

**BizInt Smart Charts**

*for Patents*

**BizInt Smart Charts**

*Reference Rows™*



# Reference Rows: Selection View

Unique fields are easily integrated in BizInt Smart Charts Reference Rows

Enhanced Title	Indications	Patent Type	Classifications	Family Status			
				Pub No.	State	Status	Expiry
Monoclonal antibodies and vaccines against epitopes on the Ebola virus glycoprotein ✓	Ebola virus infection ✓	Product ✓	Anti-Infectives Biologicals and Immunologicals ✓				
				WO200116183	DEAD	LAPSED	2006-03-26 ✓
				AU7089600	DEAD	LAPSED	2006-03-26
				US6630144	ALIVE	GRANTED	2020-08-29
Monoclonal antibodies against glycoprotein of Ebola Sudan Boniface (ESB) virus - useful in the diagnosis and treatment of ESB virus infection. ✓	Ebola virus infection ✓	Diagnostic, Analysis and Assay Product (Macromolecule) ✓	Anti-Infectives Biologicals and Immunologicals Diagnostics ✓				
				WO2011071574	ALIVE	PENDING	2030-09-01 ✓
				EP2473525	DEAD	LAPSED	2014-08-27
				US2012164153	ALIVE	PENDING	2030-09-01
Ebola virus liposome vaccines - useful in eliciting immune responses against Ebola virus infection. ✓	Ebola virus infection ✓	Formulation ✓	Anti-Infectives Biologicals and Immunologicals Pharmaceuticals ✓				
				WO2012050193	DEAD	LAPSED	2013-12-03 ✓
				JP2014005205	ALIVE	PENDING	2030-10-14

# Reference Rows: HTML exports


As seen in the fully integrated view

	Enhanced Title	Indications	Patent Type	Classifications	Family Status				Database
					Pub No.	State	Status	Expiry	
2.	Monoclonal antibodies and vaccines against epitopes on the Ebola virus glycoprotein	Ebola virus infection	Product	Anti-Infectives Biologicals and Immunologicals	WO200116183	DEAD	LAPSED	2006-03-26	2.1 CORTP   <a href="#">link</a> 2.2 FAMPAT   <a href="#">link</a>
					AU7089600	DEAD	LAPSED	2006-03-26	
					US6630144	ALIVE	GRANTED	2020-08-29	
	2.1 CORTP	2.1 CORTP	2.1 CORTP	2.1 CORTP				2.2 FAMPAT	
3.	Monoclonal antibodies against glycoprotein of Ebola Sudan Boniface (ESB) virus - useful in the diagnosis and treatment of ESB virus infection.	Ebola virus infection	Diagnostic, Analysis and Assay Product (Macromolecule)	Anti-Infectives Biologicals and Immunologicals Diagnostics	WO2011071574	ALIVE	PENDING	2030-09-01	3.1 CORTP   <a href="#">link</a> 3.2 FAMPAT   <a href="#">link</a>
					EP2473525	DEAD	LAPSED	2014-08-27	
					US2012164153	ALIVE	PENDING	2030-09-01	
	3.1 CORTP	3.1 CORTP	3.1 CORTP	3.1 CORTP				3.2 FAMPAT	
4.	Ebola virus liposome vaccines - useful in eliciting immune responses against Ebola virus infection.	Ebola virus infection	Formulation	Anti-Infectives Biologicals and Immunologicals Pharmaceutics	WO2012050193	DEAD	LAPSED	2013-12-03	4.1 CORTP   <a href="#">link</a> 4.2 FAMPAT   <a href="#">link</a>
					JP2014005205	ALIVE	PENDING	2030-10-14	
	4.1 CORTP	4.1 CORTP	4.1 CORTP	4.1 CORTP				4.2 FAMPAT	
5.	Chimeric filovirus glycoproteins useful in vaccines against Ebola and Marburg virus infections	Marburg virus infection	Product	Anti-Infectives Biologicals and Immunologicals	WO02079239	DEAD	LAPSED	2006-03-29	5.1 CORTP   <a href="#">link</a> 5.2 FAMPAT   <a href="#">link</a>
		Ebola virus infection			US7731975	DEAD	LAPSED	2014-06-08	
	5.1 CORTP	5.1 CORTP	5.1 CORTP	5.1 CORTP				5.2 FAMPAT	

# Integrate data from related records

Enhanced Title	Database	Patent Family			Family Status				Alignment	% Identity			
		Patent	Kind	Date	Pub No.	State	Status	Expiry					
5. Methods for detecting the presence of isolated attenuated hEbola virus - useful as vaccines.	5.1 FAMPAT   <a href="#">link</a>	WO 201048615	A2	2010-04-29	WO2010048615	ALIVE	PENDING	2029-10-26	Q:	1	SFKAALSSL	9	100.00
	5.2 CORTP   <a href="#">link</a>	CA 2741523	A1	2010-04-29	AU2009308422	ALIVE	PENDING	2029-10-26					
	5.3 GPATPRT   <a href="#">link</a>	AU 2009308422	A1	2010-04-29	CA2741523	ALIVE	PENDING	2029-10-26					
	5.4 GPATPRT   <a href="#">link</a>	WO 201048615	A3	2010-11-25	EP2350270	ALIVE	PENDING	2029-10-26	S:	279	SFKAALSSL	287	
	5.5 GPATNUC   <a href="#">link</a>	EP 2350270	A2	2011-08-03	IN3817/DELNP/2011	ALIVE	PENDING	2029-10-26					
	5.6 GPATNUC   <a href="#">link</a>	EP 2350270	A4	2012-04-11	US2012251502	ALIVE	PENDING	2029-10-26					
	5.7 GENESEQ   <a href="#">link</a>	US 20120251502	A1	2012-10-04									
		IN 2011DN03817	A	2013-09-27									
	5.2 CORTP			5.1 FAMPAT				5.1 FAMPAT				5.3 GPATPR	5.3 GPATPR
6. Recombinant biocontrol filovirus	6.1 FAMPAT   <a href="#">link</a>	WO 2009128867	A2	2009-10-22	WO2009128867	DEAD	LAPSED	2010-09-08	Q:	1	SFKAALSSL	9	100.00
	6.2 GENESEQ   <a href="#">link</a>	WO 2009128867	A3	2010-03-25									
									S:	1	SFKAALSSL	9	
	6.1 FAMPAT			6.1 FAMPAT				6.1 FAMPAT				6.2 GENESE	6.2 GENESE
7. Nucleic acid comprising a polynucleotide encoding a modified filovirus glycoprotein - useful as vaccines against filovirus infections, specifically Ebola virus.	7.1 FAMPAT   <a href="#">link</a>	WO 200637038	A1	2006-04-06	WO2006037038	ALIVE	PENDING	2025-09-27	Q:	1	HNTFPVYKLDISEATQVE	17	100.00
	7.2 CORTP   <a href="#">link</a>	CA 2581840	A1	2006-04-06	AU2005289439	ALIVE	GRANTED	2025-09-27					
	7.3 GPATPRT   <a href="#">link</a>	AU 2005289439	A1	2006-04-06	CA2581840	ALIVE	GRANTED	2025-09-27					
	7.4 GPATPRT   <a href="#">link</a>	WO 200637038	A9	2006-05-26	EP1797113	ALIVE	GRANTED	2025-09-27	S:	389	HNTFPVYKLDISEATQVE	405	
	7.5 GPATPRT   <a href="#">link</a>	WO 200637038	B1	2006-08-03	IL182225	DEAD	LAPSED	2012-09-20					
	7.6 GPATPRT   <a href="#">link</a>	EP 1797113	A1	2007-06-20	IN2674/DELNP/2007	ALIVE	GRANTED	2025-09-27					
	7.7 GPATPRT   <a href="#">link</a>	IN 2007DN02674	A	2007-08-03	JP2008514203	ALIVE	GRANTED	2025-09-27					
	7.8 GENESEQ   <a href="#">link</a>	IL 182225	D0	2007-09-20	US2009232841	ALIVE	GRANTED	2027-06-07					
	7.9 GENESEQ   <a href="#">link</a>	JP 2008514203	A	2008-05-08	US8101739	ALIVE	GRANTED	2027-06-07					
	7.10 GENESEQ   <a href="#">link</a>	US 20090232841	A1	2009-09-17	US2012156239	ALIVE	PENDING	2025-09-27					
		AU 2005289439	B2	2011-12-01									
		US 8101739	B2	2012-01-24									
		US 20120156239	A1	2012-06-21									
		JP 5046941	B2	2012-10-10									
		IN 259912	B	2014-04-04									
		CA 2581840	C	2014-08-05									
		EP 1797113	B1	2014-11-26									
	7.2 CORTP			7.1 FAMPAT				7.1 FAMPAT				7.3 GPATPR	7.3 GPATPR

# Reference Rows: user-defined rules





# Summarize data from related records

	Title	Database	Patent Assignee	Query ID	Sequence Locations				
					Seq. ID Number	% Identity	Length	Location	
1.	PRODUCTION OF PEPTIDES IN PLANTS AS VIRAL COAT PROTEIN FUSION	1.1 Patbase   link 1.2 GENESEQ   link	LARGE SCALE BIOLOGY CORP.	query2	WO20050108564-0101	100.00	17	Example 6; SEQ ID NO 101;	1.2
		1.1 Patbase							1.2 GENESE
2.	Chimeric ebola virus envelopes and uses therefor	2.1 Patbase   link 2.2 GPATPRT   link 2.3 GPATPRT   link 2.4 GPATPRT   link 2.5 GPATPRT   link 2.6 GENESEQ   link 2.7 GENESEQ   link	UNIV PENNSYLVANIA.	query2 query5	US20050255123-0001 WO03092582-0009 WO03092582-0001 US20050255123-0009 WO20030092582-0001 WO20030092582-0009	100.00 100.00 100.00 100.00 100.00 100.00	17 498 17 498 17 498	claim: 17 claim: 17 claim: 17 claim: 17 Claim 17; SEQ ID NO 1; 107pp; English. Claim 17; SEQ ID NO 9; 107pp; English.	2.2 2.3 2.4 2.5 2.6 2.7
		2.1 Patbase							2.6 GENESE
3.	ANTIGEN FRAGMENT AND TRUNCATION BASED ON EBOLA VIRUS ENVELOPE PROTEIN AS WELL AS APPLICATION	3.1 Patbase   link 3.2 GENESEQ   link 3.3 GENESEQ   link	BIOENGINEERING RES INST ACAD MEDICAL SCI.	query2	CN103864904-0008 CN103864904-0002	100.00 100.00	 17	 Example 1; SEQ ID NO 2; 28pp; Chinese.	3.2 3.3
		3.1 Patbase							3.2 GENESE
4.	HUMAN EBOLA VIRUS SPECIES AND COMPOSITIONS AND METHODS THEREOF	4.1 Patbase   link 4.2 GPATPRT   link 4.3 GPATPRT   link 4.4 GPATNUC   link 4.5 GPATNUC   link 4.6 GENESEQ   link	US DEPT HEALTH & HUMAN SERVICES.	query7 query5	US20120251502-0011 EP2350270-0011 US20120251502-0027 EP2350270-0027 WO20100048615-0027	100.00 100.00 100.00 100.00 100.00	9 9 20 20 20	claim: 8; 11; 12 TBD (information not in GQ-Pat) probable disclosure (not found by automated parsing) TBD (information not in GQ-Pat) Claim 30; SEQ ID NO 27; 98pp; English.	4.2 4.3 4.4 4.5 4.6
		4.1 Patbase							4.6 GENESE



# Sequence Summary Recipe

- Recipe for creating the sequence summary table at [bizint.com/cookbook](http://bizint.com/cookbook)
- Create Subtable from any columns you want  
NOTE: alignment loses fixed width formatting
- In Reference Rows, choose Summarize All Values column rule
- Export chart

# Tools for integrating patent data

- **Combine charts** using **File|Combine** command
- **Identify related records** using the **“Identify Common Patent Family”** tool.
- Use **BizInt Smart Charts Reference Rows** to summarize related records in a single row.
- You aren't limited to grouping by patent family!

**BizInt Smart Charts**

*for Patents*

**BizInt Smart Charts**

*Reference Rows™*

# Summarize at Patent or Sequence Level

- Always start with Tools | Identify Common Patent Family to create the Common Family column (this is a “magic” column)
- Replace contents of the Common Family column with the data you want to group by  
Select column, copy  
Select Common Family, paste
- Patent level: Patent Number
- Sequence level: Sequence ID (pub+seqidno)

# "Summary Record" export

1.	<b>Title:</b> Modulating expression of a target nucleic acid comprises providing to the cell a guide RNA including a transcriptional activator or repressor domain as a fusion protein, and providing to the cell a nuclease null Cas9 protein			
	<b>Database:</b> Derwent World Patents Index Derwent World Patents Index <a href="#">GQPAT Gold+ Proteins</a> <a href="#">GQPAT Gold+ Proteins</a> <a href="#">PatBase</a> <a href="#">FAMPAT</a>			
	<b>Patent Family:</b>	<b>Patent</b>	<b>Kind</b>	<b>Date</b>
		<a href="#">US 2014356959</a>	A	2014-12-04
		<a href="#">US 2014356956</a>	A	2014-12-04
		AU 2014274939	AA	2014-12-11
		<a href="#">WO 14197568</a>	A2	2014-12-11
		<a href="#">WO 14197568</a>	A3	2015-03-12
		CA 2914638	AA	2015-12-04
		KR 20160014036	A	2016-02-05
	<b>Family Status:</b>	<b>Pub No.</b>	<b>State</b>	<b>Status</b> <b>Expiry</b>
		US 20140356956 A1	ALIVE	PENDING      2034-06-04
		US 9267135 B2	ALIVE	GRANTED      2034-06-04
	<b>Probable Assignee:</b> PRESIDENT AND FELLOWS OF HARVARD COLLEGE			
	<b>Sequence Locations:</b>	<b>Seq. ID Number</b>	<b>% Identity</b>	<b>Length</b> <b>Location</b>
		US20140356959-0001	100.00	1368      probable disclosure (not found by automated parsing)
		US20140356956-0001	100.00	1368      probable disclosure (not found by automated parsing)
	<b>Notes</b>			
	<b>Alignment:</b>			
	Q:	1	MDKKYSIGLDIGTNSVGWAVITDEYKVPSSKFKVLGNTDRHSIKKNLIGALLFDSGETAE	60
	S:	1	MDKKYSIGLDIGTNSVGWAVITDEYKVPSSKFKVLGNTDRHSIKKNLIGALLFDSGETAE	60

# Agenda

- Building IP Sequence reports
- GenomeQuest data enhancements
- Hit Structure reports
- Other data types





4.	<b>Title:</b>	BIOSYNTHETIC PRODUCTION OF CAFFEINE
	<b>Database:</b>	GQPAT Gold+ Nucleotides
	<b>Num. Sequences:</b>	84
	<b>Unique Family Sequence ID:</b>	19d7ecbc7eed4810855f15d1dc2b509f_1155_56074947
	<b>Sequence Listing Equivalents:</b>	EP3223621; US20170362616; WO2016085929
	<b>Patent Assignee:</b>	CODEXIS; COCA COLA
	<b>Hyperlinks:</b>	<a href="#">Source</a>   EP3223621



- The “publisher” link for a GQPAT sequence goes to the sequence in the context of your query.
- Links were broken for a while...  
Please let us know when you see problems with any platform we support!



- Version 4.6 includes several improvements
- Patent Assignee now comes from Normalized Patent Assignee when present
- Number of Sequences available in column

Would # nucleotides/proteins be useful?  
# claimed sequences?



- Added Unique Family Sequence ID
- Possible development: each unique sequence only appears once per family
- Added Sequence Listing Equivalents
- Useful in publication-level reports

# Agenda

- Building IP Sequence reports
- GenomeQuest data enhancements
- Hit Structure reports
- Other data types



# Index Terms

- Version 4.5 includes major improvements to Index Terms display
- Index Terms appear as single paragraphs in record display
- Hit Index Terms extracted on New STN
- Table of Hit Index Terms with RN, RL, and Notes for each IT
- Classic STN and New STN

# Index Terms

Hit Index Terms  
table in the chart

Improved Index Terms  
display in the records

Hit Index Terms		
RN	Role	Notes
1655492-02-6P	Preparation (PREP); Reactant (RCT); Reactant or Reagent (RACT); Synthetic Preparation (SPN)	prepn. and biol. applications of tricyclic benzoxaborole comps.
1364682-96-1P 1364683-03-3P	Biological Study (BIOL); Pharmacological Activity (PAC); Preparation (PREP); Synthetic Preparation (SPN); Therapeutic Use (THU); Uses (USES)	prepn. of benzoxaborole derivs. useful for treating bacterial infections
1364684-69-4P 1364684-75-2P	Preparation (PREP); Reactant (RCT); Reactant or Reagent (RACT); Synthetic Preparation (SPN)	prepn. of benzoxaborole derivs. useful for treating bacterial infections

## Index Terms

1364682-96-1P 1364683-03-3P RL: Biological Study (BIOL); Pharmacological Activity (PAC); Preparation (PREP); Synthetic Preparation (SPN); Therapeutic Use (THU); Uses (USES) (prepn. of benzoxaborole derivs. useful for treating bacterial infections)

1364684-69-4P 1364684-75-2P RL: Preparation (PREP); Reactant (RCT); Reactant or Reagent (RACT); Synthetic Preparation (SPN) (prepn. of benzoxaborole derivs. useful for treating bacterial infections)

# Hit Structures

- Work in progress now to capture hit structures both Classic STN and New STN
- Hit structures supported for New STN starting with Version 4.5
- Initial display is in the Summary Records export
- Summary Records can include abstract image in addition to hit structures.
- Limited display options for display today


# Support for hit structures in summary records

3.	<b>Title:</b> Boron-containing small molecules
<b>Basic Patent Number:</b>	CA 2810021 A1
<b>Inventor(s):</b>	Hernandez, Vincent S.; Ding, Charles; Plattner, Jacob J.; Alley, Michael Richard Kevin; Rock, Fernando; Zhang, Suoming; Easom, Eric; Li, Xianfeng; Zhou, Ding
<b>Patent Assignee:</b>	Anacor Pharmaceuticals, Inc., United States (US)
<b>International Patent Class:</b>	A61K0031/69; A61P0031/04; C07F0005/02
<b>CA Classification:</b>	Organometallic And Organometalloidal Compounds (29)

## Hit Structures:

### 1364682-96-1


1-Propanol, 3-[[[3-(aminomethyl)-4-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborol-7-yl]oxy]-, 2,2,2-trifluoroacetate (1:2)



Biological Study (BIOL); Pharmacological Activity (PAC); Preparation (PREP); Synthetic Preparation (SPN); Therapeutic Use (THU); Uses (USES)


prepn. of benzoxaborole derivs. useful for treating bacterial infections

### CM2 CRN 76-05-1



### 1364683-03-3

1-Propanol, 3-[[[3-(aminomethyl)-4-chloro-1,3-dihydro-1-hydroxy-2,1-benzoxaborol-7-yl]oxy]-, hydrochloride (1:1)



Biological Study (BIOL); Pharmacological Activity (PAC); Preparation (PREP); Synthetic Preparation (SPN); Therapeutic Use (THU); Uses (USES)

prepn. of benzoxaborole derivs. useful for treating bacterial infections

• HCl

- New STN - now
- Classic STN - coming soon




# Hit Structures - Version 4.6

- Support for Combine and Update
- Support in Reference Rows
- Can have both sequence alignments and hit structures in the same family in a Summary Records export



# Structure-oriented table

## Index of Hit Structures

	SUBSTANCE	STRUCTURE	REFERENCE
1	<b>1655492-02-6</b>  2,1-Benzoxaborole, 4-fluoro-1,3-dihydro-1-hydroxy-3-(nitromethyl)-7-[2-(phenylmethoxy)ethoxy]-		<ul style="list-style-type: none"> <li>• prepn. and anti-mycobacterial activity of benzoxaborole compds. <a href="#">Reference 1</a></li> <li>• prepn. and biol. applications of tricyclic benzoxaborole compds. <a href="#">Reference 2</a></li> </ul>
2	<b>1364682-96-1</b>  1-Propanol, 3-[[[3-(aminomethyl)-4-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborol-7-yl]oxy]-, 2,2,2-trifluoroacetate (1:2)	<p>CM1 CRN 1364682-95-0</p>  <p>CM2 CRN 76-05-1</p> 	<ul style="list-style-type: none"> <li>• prepn. of benzoxaborole derivs. useful for treating bacterial infections <a href="#">Reference 3</a></li> </ul>

# Index of Hit Structures

- A table of contents to the hit structures
- Each RN appears once, with links to all of the corresponding CAplus documents
- Possible options for the link - PN.B, AN, Answer number, Row number in chart
- Initial deployment as part of a Summary Record export


# Hit Structures - Next Steps

- Classic STN hitstr support
- Index of Hit Structures
- Improved formatting of display
- Full resolution structure images in export
- Options for content

# Hit Structures - Future Applications

- DCR + DWPI
- ReaxysSUB + ReaxysBIB
- MARPAT
- DWPIM?
- Hit Structures in other export formats

# Hit Structures - Future Applications




The dialog box is titled "Summary Record Export Options". It contains a descriptive text: "The Summary Record export shows the columns (fields) visible in your chart." Below this, there are four checked checkboxes: "Number the records", "Start each record on new page", "Include Links section", and "Include editable Notes section". A section titled "You may also include the following information for the record:" follows, with three checked checkboxes: "Include Claims", "Include Alignment", and "Include Hit Structures". At the bottom, there are three buttons: "OK", "Cancel", and "Help".

- Summary Records export allows both Alignment and Hit Structures
- Combine a chart with both Sequence and Structure searches
- Reference Rows will show both in the same family



# Agenda

- Building IP Sequence reports
- GenomeQuest data enhancements
- Hit Structure reports
- Other data types



*for Patents*

## Patent Databases

*Provide data on patents filed worldwide*

- **STN** – Classic & **New**
- Questel Orbit.com (incl **FULLPAT**)
- Minesoft PatBase
- Thomson Innovation, Cortellis IP, Integrity Patents
- LexisNexis TotalPatent
- **GQ Life Sciences LifeQuest**



*for Patents*

## Literature Databases

*Provide data on technical and scientific publications*

- Biomedical (Embase, Biosis, Medline)
- Scientific (SciSearch, Chemical Abstracts, PQSciTech, etc)
- Technical (INSPEC, RAPRA, GEOREF, etc.)
- Hosts: STN (Classic & New), ProQuest Dialog, Ovid, PubMed



# NEW! NCT number and DOI links


## Alzheimers Clinical Trials

	<i>Title</i>	<i>Source</i>	<i>Clinical Trials</i>	<i>DOI</i>	<i>Publication Date</i>
1 Link	<b>Centre- versus home-based exercise among people with mci and mild dementia: study protocol for a randomized parallel-group trial.</b>	BMC geriatrics (2018-01-25), vol. 18, no. 1, p. 27.	NCT02774720	10.1186/s12877-017-0684-0	2018-01-25
2 Link	<b>Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.</b>	The New England journal of medicine (2018-01-25), vol. 378, no. 4, p. 321-330.	NCT01900665	10.1056/NEJMoa1705971	2018-01-25
3 Link	<b>Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.</b>	JAMA (2018-01-09), vol. 319, no. 2, p. 130-142.	NCT01955161 NCT02006641 NCT02006654	10.1001/jama.2017.20373	2018-01-09
4 Link	<b>Placebo Effects in the Treatment of Noncognitive Symptoms of Alzheimer's Disease: Analysis of the CATIE-AD Data.</b>	The Journal of clinical psychiatry (2017 Nov/Dec), vol. 78, no. 9, p. e1204-e1210.	NCT00015548	10.4088/JCP.17m11461	2017 Nov/Dec
5 Link	<b>Retinal Microperimetry: A New Tool for Identifying Patients With Type 2 Diabetes at Risk for Developing Alzheimer Disease.</b>	Diabetes (2017-12), vol. 66, no. 12, p. 3098-3104.	NCT02360527	10.2337/db17-0382	2017-12

# Link from NCT numbers to CT.gov

## Alzheimers Clinical Trials

	Title	Source	Clinical Trials	DOI	Publication Date
1 Link	Centre- versus home-based exercise among people with mci and mild dementia: study protocol for a randomized parallel-group trial.	BMC geriatrics (2015), vol. 18, no. 25	<a href="#">NCT02774720</a>	10.1186/s12877-017-0684-0	2018-01-25
2 Link	Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.	The New England Journal of Medicine (2016), vol. 378, no. 1, p. 32-41			
3 Link	Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.	JAMA (2016), vol. 319, no. 2, p. 151-161			
4 Link	Placebo Effects in the Treatment of Noncognitive Symptoms of Alzheimer's Disease: Analysis of the CATIE-AD Data.	The Journal of Clinical Psychiatry (2016), vol. 77, no. 11, p. e1204-1211			
5 Link	Retinal Microperimetry: A New Tool for Identifying Patients With Type 2 Diabetes at Risk for Developing Alzheimer Disease.	Diabetes Care (2016), vol. 39, no. 12, p. 2011-2017			


 U.S. National Library of Medicine

[Find Studies](#)

[ClinicalTrials.gov](#)

[Home](#) > Study Record Detail

**Centre- Versus Home-based Exercise for MCI and Early Dementia (CHIME)**



The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. [Know the risks and potential benefits](#) of clinical studies and talk to your health care provider before participating. Read our [disclaimer](#) for details.

**Sponsor:**  
University of Waterloo

**Collaborator:**  
Alzheimer's Association

**Information provided by (Responsible Party):**  
University of Waterloo

[Study Details](#)
[Tabular View](#)
[No Results Posted](#)
[Disclaimer](#)
[How to Read a Study Record](#)



# Link from DOI's to articles

## Alzheimers Clinical Trials

	Title	Source	Clinical Trials	DOI	Publication Date
1 Link	Centre- versus home-based exercise among people with mci and mild dementia: study protocol for a randomized parallel-group trial.	BMC geriatrics (2018-01-25), vol. 18, no. 1, p. 27.	NCT02774	<a href="https://doi.org/10.1186/s12877-017-0684-0">10.1186/s12877-017-0684-0</a>	2018-01-25
2 Link	Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.				
3 Link	Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: The Randomized Clinical Trials.				
4 Link	Placebo Effects in the Treatment of Noncognitive Symptoms of Alzheimer's Disease: Analysis of the CATAD Data.				
5 Link	Retinal Microperimetry: A New Tool for Identifying Patients With Type 2 Diabetes at Risk of Developing Alzheimer Disease.				


[Explore journals](#)
[Get published](#)
[About BMC](#)

### BMC Geriatrics

[Home](#)
[About](#)
[Articles](#)
[Submission Guidelines](#)

[Abstract](#)
[Background](#)
[Methods & design](#)
[Discussion](#)
[Declarations](#)
[References](#)

[Study protocol](#)
[Open Access](#)
[Open Peer Review](#)

## Centre- versus home-based exercise among people with mci and mild dementia: study protocol for a randomized parallel-group trial

Laura E. Middleton , Sandra E. Black, Nathan Herrmann, Paul I. Oh, Kayla Regan and Krista L. Lancot

BMC Geriatrics BMC series – open, inclusive and trusted 2018 18:27  
<https://doi.org/10.1186/s12877-017-0684-0> | © The Author(s). 2018  
 Received: 6 June 2017 | Accepted: 12 December 2017 | Published: 25 January 2018

 [Open Peer Review reports](#)

# Column properties for NCT and DOI links

	PII	DOI	Clinical Trials	Publication
	peds.2014-4102	10.1542/peds.2014-4102	NCT01337167	2015

Column Properties

Title: DOI

Width: 120

Sort type: Alphabetic

☐ Link patent numbers to full text in HTML export

☒ Convert DOI to links in HTML export

☐ Link NCT numbers to clinicaltrials.gov in HTML export

OK Cancel Help

- NCT numbers link to clinicaltrials.gov
- DOI currently links to doi.org
- Set your own link resolver in next release

## Drug Pipeline Databases

Provide data on drugs in development worldwide



- Citeline Pharmaprojects
- IMS R&D Focus
- Adis R&D Insight
- Thomson Reuters Cortellis
- Thomson Reuters Integrity
- And, support for **Infodesk PipelinePlus**



## Clinical Trials Databases

Provide data on drug trials worldwide

- **Commercial**: Citeline TrialTrove  
Adis Clinical Trials Insight  
Cortellis Trials Intelligence
- **Public**: ClinicalTrials.gov, **WHO ICTRP**,  
**EudraCT**
- **Biomedical literature** on Ovid, ProQuest  
Dialog, PubMed, STN



- Clean-up, filter and visualize information from BizInt Smart Charts reports.
- Piano Chart - direct to PowerPoint
- Version 10 available today




# “Cookbook” of techniques

- The **Cookbook** is a collection of sample **reports and visualizations** which you can create with the BizInt Smart Charts product family.

➔ *Updated February 2018.*

[bizint.com/Cookbook](http://bizint.com/Cookbook)





Software for  
Business Intelligence

**BizInt Smart Charts**

Questions?

[www.bizint.com](http://www.bizint.com)